Histogenics Corporation announced that as part of the restructuring plan and reduction in force, E. Lynne Kelley, M.D., FACS, Chief Medical Officer, and Donald Haut, Ph.D., Chief Business Officer, have separated from service with the Company. Drs. Kelley and Haut's employment with the Company terminated effective January 23, 2019.